Appointment dossier — Prostate Cancer
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Prostate Cancer
- Fuzuloparib — Review evidence · 1 positive · PMID 34118019
- Genistein — Review evidence · 1 positive · PMID 42133114
- Olaparib — Review evidence · 1 positive · PMID 36341199
- Relacorilant — Review evidence · 1 positive · PMID 42334771
- Carboplatin — Review evidence · 0 positive · PMID 37485216
- Durvalumab — Review evidence · 0 positive · PMID 37485216
- Etoposide — Review evidence · 0 positive · PMID 37485216
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT06855277 · Phase 3 — Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC (United States)
- NCT04423211 · Phase 3 — Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging (United States)
- NCT04704505 · Phase 2 — Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) (United States)
- NCT07341737 · Phase 1 / Phase 2 — SL-28 for Advanced Solid Tumours (Australia)
- NCT07476001 · Phase 2 — Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC (United States)
- NCT07686380 · Phase 2 — IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy (United States)
- NCT06492122 · Phase 1 — Study With [225Ac]Ac-FL-020 in mCRPC Participants (United States)
- NCT06067295 — Longitudinal Advanced Prostate Cancer Cohort (LAPCC) (United States)
- NCT07526675 — Concomitant Trans-Perineal Prostate Biopsy and Ablation (Bioblation) for Prostate Cancer (Egypt)
- NCT06171139 — Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer (United States)
- NCT07463092 — Creatine Supplementation and Resistance Training to Improve Sarcopenia Parameters in Patients With Prostate Cancer After Androgen Deprivation Therapy (Brazil)
- NCT06138067 — Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer Patients (United States)
- NCT05767307 — Danish Prostate Cancer Consortium Study-1 (Denmark)
- NCT07559201 — Theranostic Applications of Radionuclides in Prostate Cancer (China)
- NCT02724670 — Study of MR-based IGRT for Prostate Cancer (Germany)
- NCT00969111 — Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy (United States)
- NCT06292897 — Using Tissue-based Spatial Data to Understand How Obesity-related Tumor Metabolites Fuel Prostate Cancer Progression (Italy)
- NCT06700057 — Clinical and Dosimetric Study of Patients Treated With 177Lu-PSMA-617 for Prostate Cancer. (France)
Most-relevant first: trials that name Prostate Cancer, then broader trials you may still qualify for. 1232 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.
Questions to ask your oncologist
- Of the open trials I found (for example NCT06855277), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?
- Should my tumor tissue be stored (biobanked) for future testing or trials?